Evidence map›Paper›PMID 40707133›Full record

ArticleJournal for immunotherapy of cancer2025

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

Melissa J Khaw, Nicholas A Zorko, Philippa R Kennedy, Laura E Bendzick, Madison Shackelford, Carly Selleck, Peter Hinderlie, Joshua T Walker, Yvette Soignier, Riley C Lyons and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Melissa J Khaw *University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Nicholas A Zorko *University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0001-7021-968X
Philippa R KennedyUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0003-0239-5440
Laura E BendzickUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Madison ShackelfordUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Carly SelleckUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Peter HinderlieUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Joshua T WalkerUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Yvette SoignierUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Riley C LyonsUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Elise L FeminoUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Terran StengerUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Tumpa DasguptaUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Laura E KotzUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Mihir ShettyUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Shee Kwan PhungUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Eng Hock LeeDepartment of Electrical and Computer Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Quynhanh LuXcell Biosciences, San Francisco, California, USA.
James LimXcell Biosciences, San Francisco, California, USA.
Paolo P ProvenzanoDepartment of Biomedical Engineering, University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, USA.
Naomi FujiokaUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Zachary B DavisUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Melissa A GellerUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
John E WagnerUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Margaret L MacMillanUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.
Martin FelicesUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA mfelices@umn.edu.ORCID http://orcid.org/0000-0002-5945-0634
Jeffrey S MillerUniversity of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumorsR35CA283892 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · 2023 to 2026
$3.7M
NCI NIH HHS P01 CA111412NCI NIH HHS R35 CA283892
6 · The paper itself

Abstract

backgroundPatients with head and neck squamous cell carcinoma (HNSCC), particularly the human papillomavirus negative (HPV

methodsThe B7H3 TriKE was generated using a mammalian expression system. Its functionality was evaluated using flow cytometry-based NK cell degranulation, cytokine production, proliferation and live cell imaging cytotoxicity assays. Models of acute and prolonged hypoxia (1% oxygen) were carried out to assess tumor killing. Tumor progression, NK cell persistence, and survival differences between IL-15-treated and TriKE-treated mice were studied using NOD-scidIL2Rg

resultsHigh B7-H3 expression was found in HPV

conclusionsThe B7H3 TriKE is a novel immunotherapeutic approach that can overcome hypoxic suppression of NK cells in the HNSCC TME. These highly translational studies present an innovative therapy for patients with HNSCC and will be developed further for clinical application.

Indexed as

B7 AntigensHead and Neck NeoplasmsKiller Cells, NaturalSquamous Cell Carcinoma of Head and NeckAnimalsCell Line, TumorFemaleHumansMiceTumor MicroenvironmentXenograft Model Antitumor AssaysB7 AntigensCD276 protein, humanCytokineHead and Neck CancerImmunotherapyNatural killer - NKTumor microenvironment - TME

Identifiers

PMID40707133
PMCPMC12306285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.